News | July 04, 2023
Biocon Biologics' Hulio Biosimilar to Humira now available in the US
The launch of HULIO in the United States is an important milestone for Biocon Biologics
The launch of HULIO in the United States is an important milestone for Biocon Biologics
Alvotech expects AVT02 (adalimumab) will be marketed in the U.S., subject to regulatory approval, on July 1, 2023
Second interchangeable biosimilar product approved by agency
Shilpa Biologicals has developed high concentration adalimumab (100 mg/mL)
The approval marks a significant milestone for the American pharmaceutical company in the field of UC
The transfer of the distribution rights will strengthen Sandoz's immunology and biosimilar portfolio
The drug exhibited greater treatment persistence and control of moderate-to-severe PsO symptoms compared to secukinumab and ixekizumab
The agreement between Eli Lilly and Janssen was established to allow the two companies to share resources for the goal of accelerating the evaluation of the respective companies’ assets, mirikizumab and Tremfya (guselkumab).
The hybrid congress will take place from 1-4 June in Copenhagen, as well as virtually
All intellectual-property disputes related to the market entry of Alvotech’s AVT02 (adalimumab) in the U.S. and Europe are now resolved
Subscribe To Our Newsletter & Stay Updated
